NCT02692963View on ClinicalTrials.gov

Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

February 28, 2017

Conditions
MalariaPlasmodium Falciparum
Interventions
BIOLOGICAL

BCG vaccination

BCG vaccine InterVax

Trial Locations (1)

6525 GA

Radboud university medical center, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT02692963 - Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection | Biotech Hunter | Biotech Hunter